Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients

Table 1 Outcome results of major randomized phase III trials in the first-line setting in metastatic colorectal cancer patients

Ref.	Regimen	n	Previous adjuvant treatment	ORR	Median PFS (mo)	Median OS (mo)	Post-study therapy
Hurwitz et al[80]Tebbutt et al[119]	IFL	411	28%	34.8%	6.2	15.6	50%
Hurwitz et al[80]	IFL+bevacizumab	402	24%	44.8%	10.6	20.3	50%
Cunningham et al[118]	Capecitabine	140	18.6%	10%	5.1	16.8	37%
	Capecitabine + bevacizumab	140	32.1%	19%	9.1	20.7	37%
Saltz et al[8]	XELOX/FOLFOX	701	25%1	38%	8	19.9	53%
	XELOX/FOLFOX + bevacizumab	699	24%1	38%	9.4	21.3	46%
Heinemann et al[81]	FOLFIRI + cetuximab	297	22.1%	62%	10	28.7	65.7%
	FOLFIRI + bevacizumab	295	18.9%	58%	10.3	25	61.7%
	Capecitabine	156	22%	30.3%	5.7	18.9	68%
Tebbutt et al[119]	Capecitabine + bevacizumab	157	28%	38.1%	8.5	18.9	62%
	Capecitabine + bevacizumab + MMC	158	16%	45.9%	8.4	16.4	61%
Falcone et al[12]	FOLFOXIRI + bevacizumab	252	12%	65%	12	31	NA3
	FOLFIRI + bevacizumab	256	12%	53%	9.7	25.8	NA3
Van Cutsem et al[82]	FOLFIRI	599	18.9%	39.7%	8.4	20	71.7%
	FOLFIRI + cetuximab	599	17.4%	57.3%	9.9	23.5	66%
Maughan et al[91]	XELOX/FOLFOX2	815	25%1	57%	8.6	17	62%
	XELOX/FOLFOX + cetuximab	815	25%1	64%	8.6	17.9	56%
Tveit et al[120]	FLOX	185	8%1	41%	7.9	20.4	73.5%
	FLOX + cetuximab	194	9%1	49%	8.3	19.7	75.8%
	FLOX intermittently + cetuximab	187	10%1	47%	7.3	20.3	64.2%
Douillard et al[90]	FOLFOX4	590	15%1	48%	8	19.7	63%
	FOLFOX4 + panitumumab	593	16.1%1	55%	9.6	23.9	53%
Schmoll et al[89]	FOLFOX + bevacizumab	713	19%	47.3%	10.3	21.3	23.8%
	FOLFOX + cediranib	709	17%	46.3%	9.9	22.8	28.2%
Díaz-Rubio et al[60]	XELOX + bevacizumab	239	13%1	47%	10.4	23.2	72%
	XELOX + bevacizumab→bevacizumab	241	17%1	49%	9.7	20	74%

¹No previous oxaliplatin-based treatment allowed;

²Both Arm A (continuously) and Arm B (intermittently) have been considered;

³Data will be available in 2014. ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; IFL: Irinotecan, fluorouracil, leucovorin therapy; FOLFIRI: 5-fluorouracil and irinotecan; XELOX: Capecitabine/oxaliplatin.